A Study of IBI363 in Subjects With Advanced Melanoma - Trial NCT06081920
Access comprehensive clinical trial information for NCT06081920 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Innovent Biologics (Suzhou) Co. Ltd.
Timeline & Enrollment
Phase 1/2
Oct 19, 2023
Jul 31, 2026
Primary Outcome
Phase โ b: AE๏ผAdverse event๏ผ,Phase โ b: RP2D๏ผRecommended phase 2 dose๏ผ,Phase โ ก๏ผORR๏ผObjective response rate๏ผ
Summary
This is an open-label, multicenter Phase Ib/II study to evaluate the safety, tolerability,
 and efficacy of IBI363 in advanced melanoma patients
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06081920
Non-Device Trial